Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-05-02

Clinical Trial Update: A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the efficacy and safety of three doses of vildagliptin in adults with type 2 diabetes. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED